Significant protocol amendments have been made to the ongoing phase 3 VIKTORIA-2 clinical trial (NCT06757634).The study, ...

CAR T therapy spreads beyond academic centers, but insurance, cost and policy gaps keep most eligible lymphoma patients from ...

FDA fast track status was supported by two monotherapy responses in MSI-H colorectal cancer, including one complete response ...

A new program for young cancer patients breaks disease silos, showing how multidisciplinary teamwork improves coordination, ...

Complete response at 3 months was 79.6% (191/240), with duration-of-response estimates showing a gradual attrition over time ...

Dr. Doroshow addresses financial toxicity as a central concern in Sandra's case and broader challenge in HER2-directed ...

During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.

Allogeneic hematopoietic cell transplantation (alloHCT) using tremtelectogene empogeditemcel (trem-cel), a CRISPR–Cas9–edited ...

Andrzej Jakubowiak, MD, PhD, director of the multiple myeloma program at the University of Chicago, discusses the definitive results of the phase 3 ATLAS trial (NCT02659293), recently published in The ...

Dr. Leal addresses diagnostic challenges with newer therapies, particularly tarlatamab's potential neurologic side effects ...

Dr. Leal introduces amifampridine, an FDA-approved oral potassium channel blocker that increases acetylcholine release at ...

First-line treatment selection in HER2-mutant NSCLC balances route of administration, efficacy data by mutation subtype, and ...